Table 3. Clinical Response to CSA... | American Society of Hematology

Table 3.

Clinical Response to CSA Therapy

Patient	CSA Dose Used to Induce Response (mg every 12 h)	Days to ANC > 1.5 × 10⁹/L	Maintenance CSA Dose (mg every 12 h)	Follow-Up (yr)	Status
1	180	75	50	8.5+	Alive, nonneutropenic
2	100	21	130 (every other day)	8.0+	Alive, nonneutropenic
3	300	60	275	1.7	Died, metastatic melanoma
4	100	60	200/100 (every other day)	4.6	Died, postoperative complications
5	200	30	100	2.0+	Alive, nonneutropenic

Patient	CSA Dose Used to Induce Response (mg every 12 h)	Days to ANC > 1.5 × 10⁹/L	Maintenance CSA Dose (mg every 12 h)	Follow-Up (yr)	Status
1	180	75	50	8.5+	Alive, nonneutropenic
2	100	21	130 (every other day)	8.0+	Alive, nonneutropenic
3	300	60	275	1.7	Died, metastatic melanoma
4	100	60	200/100 (every other day)	4.6	Died, postoperative complications
5	200	30	100	2.0+	Alive, nonneutropenic